Chemotherapy and Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Rapid Recommendation Update.
Beverly MoyR Bryan RumbleLisa Anne Careynull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual. The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options.
Keyphrases
- epidermal growth factor receptor
- healthcare
- metastatic breast cancer
- primary care
- clinical practice
- loop mediated isothermal amplification
- mental health
- tyrosine kinase
- endothelial cells
- advanced non small cell lung cancer
- public health
- emergency department
- big data
- health information
- machine learning
- induced pluripotent stem cells
- risk assessment
- deep learning
- artificial intelligence
- human health
- adverse drug